Healthcare >> CEO Interviews >> December 14, 1998
JOHN L. BISHOP is President and CEO of Vysis, Inc. Since joining the
company in 1993, Mr. Bishop has restructured and consolidated three
separate operations of Amoco Technology Company into and created Vysis,
a leader in Genomics Diagnostics. Mr. Bishop has 25 years business and
biotechnology experience with a recognized successful track record in
developing and commercializing innovative technologies and in building
diagnostics businesses. Initiating his career with American Hospital
Supply Corporation, rising through the corporate ranks, Mr. Bishop spent
three years in Japan as an Executive Vice President and Chief Executive
Officer of International Regents Corp., a joint venture between AHSC and
Green Cross Corp. He more than doubled company sales to $30 million and
oversaw design and construction of a 70,000 square foot pharmaceutically
registered facility. Following his return to the U.S., Mr. Bishop
established American Dade Chemistry Systems, which successfully
developed and marketed the Paramax clinical chemistry system.
Subsequently, Mr. Bishop served as President and Chief Operating Officer
at Gen-Probe, following which he directed the merger of Source
Scientific Systems and MicroProbe Corp. In 1991, Mr. Bishop became
Chairman and CEO of MicroProbe. He led the company through FDA clearance
for the first automated DNA-probe diagnostic system capable of
simultaneous detection and identification of multiple microorganisms,
and the first marketed directly to physicians offices. Mr. Bishop
received his B.S. in zoology from the University of Miami. He has been a
member of professional organizations, including the American Association
of Clinical Chemistry, American Association of Microbiology and the
Southern California Technical Executives Network. Profile
of its history, just to kind of set the stage for the readers?
Mr. Bishop: Okay, Vysis is a genomic disease management
